These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36944332)

  • 21. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
    Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
    Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
    Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
    Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.
    Trsova I; Hrustincova A; Krejcik Z; Kundrat D; Holoubek A; Staflova K; Janstova L; Vanikova S; Szikszai K; Klema J; Rysavy P; Belickova M; Kaisrlikova M; Vesela J; Cermak J; Jonasova A; Dostal J; Fric J; Musil J; Dostalova Merkerova M
    Mol Oncol; 2023 Dec; 17(12):2565-2583. PubMed ID: 37408496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
    Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
    Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic
    Foy A; McMullin MF
    J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
    Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.
    Pollyea DA; Kim HM; Stevens BM; Lee FF; Harris C; Hedin BR; Knapp JR; O'Connor BP; Jordan CT; Pietras EM; Tan AC; Alper S
    J Leukoc Biol; 2021 Jul; 110(1):197-205. PubMed ID: 33155727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
    Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
    Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X; Song X; Yan X
    Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.
    Qiu J; Zhou B; Thol F; Zhou Y; Chen L; Shao C; DeBoever C; Hou J; Li H; Chaturvedi A; Ganser A; Bejar R; Zhang DE; Fu XD; Heuser M
    RNA; 2016 Oct; 22(10):1535-49. PubMed ID: 27492256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
    Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
    Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
    Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
    Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.
    Cazzola M; Rossi M; Malcovati L;
    Blood; 2013 Jan; 121(2):260-9. PubMed ID: 23160465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
    Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
    Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
    Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
    Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.